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in any medium, provided the original work is properly citeEndotrophin is a cleavage product of collagenVIa3 (COL6A3). Here, we explore the
relationship between thiazolidinediones (TZDs), endotrophin and cisplatin resis-
tance in the context of a mammary tumour model. COL6A3 levels are increased in
response to cisplatin exposure in tumours. Endotrophin, in turn, causes cisplatin
resistance. The effects of endotrophin can be bypassed, either through use of
COL6 null (COL6/) mice or by administering TZDs in wild-type mice (leading to
a downregulation of endotrophin). Both approaches sensitize tumours to cispla-
tin through the suppression of endotrophin-induced epithelial–mesenchymal
transition. The beneficial effects of TZDs on cisplatin sensitivity are diminished
in COL6/ mice, whereas endotrophinþ tumours are sensitive to the TZD/
cisplatin combination. Therefore, the chemosensitization obtained with TZDs
is achieved through a downregulation of endotrophin. Treatment with an
endotrophin neutralizing antibody in combination with cisplatin completely
inhibits tumour growth of tumour allografts. Combined, our data suggest that
endotrophin levels are a strong prognostic marker for the effectiveness of the
combination therapy of TZDs with cisplatin, and neutralization of endotrophin
activity dramatically improves the therapeutic response to combination therapy.INTRODUCTION
The platinum-based chemotherapeutic agent cisplatin (cis-
diammine-dichloro-platinum) has been well established in
clinical treatment regimens due to its effectiveness on human
tumour cells, such as in the context of ovarian, lung, testicular
and breast cancer (Kelland, 2007; Lee et al, 2004; Sirohi et al,
2008). Cisplatin triggers formation of intra-strand and inter-
strand DNA-adducts, which leads to cell cycle arrest, followed
by apoptosis (Kelland, 2007). However, an inherent or acquired
resistance to cisplatin is a major clinical drawback for patients
who relapse after initial favourable responses (Galluzzi et al,iabetes Center, The
allas, TX, USA
ern Medical Center,
outhwestern Medical
1 214 648 8720;
Ltd on behalf of EMBO. Thi
C BY 3.0), which permits u
d.2012). Cisplatin resistance is a complex problemwhich involves
multiple pathways including increased drug efflux, evasion of
apoptotic pathways, a bypass of the replication checkpoint,
increased cell proliferation and increased DNA damage repair
(Galluzzi et al, 2012). To overcome the drug resistance against
platinum-based chemotherapy, combination therapies with
peroxisome proliferator-activated receptor gamma (PPARg)
agonists, the thiazolidinediones (TZDs), have been performed.
The basis for this approach is the growth inhibitory effect of
these PPARg agonists on transformed cells through both PPARg-
dependent and -independent pathways (Blanquicett et al, 2008;
Mueller et al, 1998; Palakurthi et al, 2001; Satoh et al, 2002).
PPARg is a member of the nuclear hormone receptor super-
family and a key transcription factor for adipogenesis. It is also
involved in various physiological processes, such as cell
proliferation, angiogenesis, inflammation and lipid partitioning
(Tontonoz & Spiegelman, 2008). Combination therapies with
TZDs have been shown to display beneficial effects on cancer
cell death, while also leading to a reduction of overall systemic
toxicity to these chemotherapeutic regimens (Girnun et al, 2007,
2008; Tikoo et al, 2009). However, the detailed molecular basiss is an open access article under
se, distribution and reproduction
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936underlying the beneficial effects of TZDs to platinum treatment
has yet to be documented.
In the tumour microenvironment, both stromal and cancer
cells contribute to various types of extracellular matrix (ECM)
proteins to actively remodel the microenvironment favourably
for tumour growth and metastasis. Such ECM proteins include
fibronectin, laminin, collagen I (COL1), collagen IV (COL4) and
collagen VI (COL6) and these ECM components are markedly
modulated in response to chemotherapy (Dangi-Garimella et al,
2011; Sherman-Baust et al, 2003; Su et al, 2007). They have been
suggested to cause drug resistance in solid tumours, including
small-cell lung cancer, ovarian cancer, pancreatic cancer and
breast cancer (Helleman et al, 2008; Rintoul & Sethi, 2001;
Sherman-Baust et al, 2003; Shields et al, 2012) through multiple
pathways. These include an induction of anti-apoptotic pathways
(Sethi et al, 1999), decreased drug transport (Netti et al, 2000) and
increased survival signals, such as those mediated through
integrin-based pathways (Jean et al, 2011). COL6 is composed of
three alpha chains; a1, a2 and a3. Particularly, the a3 chain of
COL6 (COL6A3) has been highlighted as a promising candidate
triggering drug resistance against platinum-based therapeutics
since its levels are vastly increased in the cisplatin-resistant cancer
cells in vitro (Sherman-Baust et al, 2003; Varma et al, 2005).
Nevertheless, the more detailed mechanism underlying how
COL6A3 regulates drug-resistance has remained elusive.
Recently, we identified endotrophin, a cleavage product
of COL6A3 that is actively involved in mammary tumour
progression through enhancing the epithelial–mesenchymal
transition (EMT), fibrosis and chemokine activity, thereby
recruiting stromal cells to the tumour microenvironment (Park
& Scherer, 2012a,b). Notably, all of these activities are
associated with acquired drug resistance. In this study, we
report increased levels of endotrophin following cisplatin
exposure. This causes cisplatin-resistance through enhancing
the EMT. Furthermore, endotrophin levels were decreased by
combination therapy with TZD, leading to a decrease of EMT,
fibrosis and vasculature, thereby enhancing cisplatin sensitivity.
In contrast, functional COL6 null mice (COL6/) that display a
reduced EMT over the course of tumour progression, failed to
show any added beneficial effects of TZDs to cisplatin. Taken
together, these results suggest that the beneficial effects of TZDs
on platinum-based chemotherapy are mediated through the
inhibition of endotrophin in mammary tumours, and that theFigure 1. TZD augments cisplatin sensitivity and correlates with the COL6A3
A. FP635/PyMT mice were given TZD containing chow (supply approx. 20 mg/kg/
(1 mg/kg) or PBS treatment was initiated at 10 weeks of age (ip., 3 times/week
fluorescence scanner (IVIS, Caliper life science). Quantified results are repre
unpaired Student’s t-test. Metastatic burden was determined by fluorescen
B. Primary cancer cells isolated from tumours in PyMT mice were implanted int
5 days). Tumour volumes were determined by caliper measurement and re
versus TZD/CIS by two-way ANOVA.
C,D. Total RNA was extracted from tumour tissues in each group. mRNA levels fo
E-cadherin, N-cadherin, Vimentin, Snail, Slug, Twist1 and Twist2 (D) were dete
mean SD (n¼7/group). p<0.05, p<0.01, p<0.001 ND/PBS versus N
E,F. EMT indices were determined by immunostaining with E-Cadherin (E) and V
Staining positive area was quantified (multiple images, n¼5/group). p¼0.
Scale bars: 100mm.
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.neutralization of endotrophin activity is a key determinant to
unleash the full beneficial effects of TZDs.RESULTS
Cisplatin augments COL6A3 levels, whereas TZDs cause a
reduction
To assess the beneficial effects of TZD (we are using mostly the
TZD rosiglitazone here) on platinum-based chemotherapies in
mammary tumour models in vivo, we used either a MMTV-
PyMT (‘‘PyMT’’) mouse model or an allograft of Met-1 cancer
cells (originating from MMTV-PyMT mammary tumours) that
we transplanted into isogenic wild-type mice. To visualize
system-wide tumour burden in vivo, we introduced an infrared-
fluorescent protein (FP635) overexpressing transgene driven by
the MMTV promoter (MMTV-FP635) into PyMT mice (Park &
Scherer, 2012b). We monitored tumour regression by utilizing
fluorescence scanning over the course of cisplatin treatment
(Fig 1A). Consistent with prior reports seen in in vitro settings
(Girnun et al, 2007), tumour growth was efficiently reduced and
pulmonary metastasis were also slightly attenuated in PyMT
mice exposed to TZDs (20mg/kg) in combination with cisplatin
(1mg/kg) compared to those mice given only cisplatin (Fig 1A).
Met-1 allografts showed a better response to the combination
of TZD with cisplatin than the response seen in PyMT mice
(Fig 1B). This may be due to PPARg-dependent activation of
intrinsic oncogenic pathways, such as wnt, or contributions
of the tumour stroma responding to a prolonged treatment of
TZDs, which may counteract their beneficial effects on cisplatin
in the PyMT mice (Saez et al, 2004). In addition, we have
previously shown that TZDs are potent inducers of the
adipokine adiponectin that we have implicated in enhanced
angiogenesis and improved cellular survival (Landskroner-Eiger
et al, 2009). Subsequent histological analysis of tumour tissues
indicated that cancer cell death was increased about twofold
with the TZD combination (Supporting Information Fig S1A).
The fact that the metallothionein (MT) levels, a molecular marker
for drug resistance (Theocharis et al, 2003), are suppressed by the
TZD combination with cisplatin, is well appreciated (Girnun et al,
2007). Consistently, immunostaining for MT in tumour tissues of
PyMTmice showed that cisplatin treatment significantly increased
the MT levels, and this was suppressed in the presence of TZDlevels.
day, rosiglitazone) or normal-diet (ND) starting at 8-weeks of age, and cisplatin
) over the course of tumour progression. Tumour burden was monitored with a
sented as mean SD (n¼ 8–9/group). p¼0.04, ND/CIS versus TZD/CIS by
ce signals in lung tissues.
o WT mice. TZD were given 5 days prior to cisplatin treatment (1 mg/kg, every
presented as mean SD (n¼ 5–6/group). p< 0.05 and p<0.001, ND/CIS
r collagens such as COL1A1, COL6A1, -A2 and -A3 (C), and EMT genes such as
rmined by qRT-PCR and normalized with 36B4. Quantitative results represent
D/CIS; ###p<0.001 ND/CIS versus TZD/CIS by two-way ANOVA.
imentin (F). Cytokeratin (epithelial cells) and DAPI (nucleus) were co-stained.
014 (E) and p¼ 0.015 (F), ND/CIS versus TZD/CIS by unpaired Student’s t-test.
"
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Figure 1.
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938(Supporting Information Fig S1B). As such, the PyMT mice serve
as a useful model to assess the beneficial effects of TZDs in
platinum-based therapeutics in vivo.
To see whether COL6 is involved in the beneficial effects of
TZDs on platinum-based therapy, we determined the expression
levels for COL6 in response to chemotherapy. The mRNA levels
of COL6A3 in tumour tissues of PyMT mice were significantly
increased in response to cisplatin treatment; this increase was
dramatically suppressed by combination with TZDs (Fig 1C).
These results indicate that COL6A3 levels may have an impact
on the degree of chemo-sensitivity between TZDs and platinum
in vivo. Nevertheless, whether and how COL6A3 directly
contributes to drug responsiveness is not known.
Cisplatin augments epithelial–mesenchymal transition,
whereas TZD attenuates it
The EMT process in tumour tissues is well known to contribute
to an acquired drug resistance (Arumugam et al, 2009; Latifi
et al, 2011). This suggests a fundamentally reduced sensitivity
of mesenchymal-like cells to chemotherapeutic approaches.
Targeting the critical factors that contribute to the EMT process,
such as Snail, Slug and Twist1, has beneficial effects for
cisplatin-based therapies (Haslehurst et al, 2012; Zhu et al,
2012), further generalizing a model that correlates the degree of
cisplatin sensitivity with the EMT status of tumour tissues.
Moreover, TZDs have been suggested to suppress EMT,
resulting in a reduced level of tumour metastasis (Reka et al,
2010). In our mouse models, the mRNA levels for transcription
factors associated with EMT, such as Snail, Slug and Twist1,
were significantly increased in response to cisplatin exposure.
The increases in critical mediators of EMT, especially the
increased levels of Twist1, were significantly attenuated
by combination treatment with TZD (Fig 1D). This supports
the idea that cisplatin induces EMT in cancer cells, and that the
beneficial effects of TZDs in the context of cisplatin exposure are
partly mediated by suppression of EMT. This is substantiated by
immunohistochemistry with critical EMT markers. Immuno-
staining with antibodies against EMT markers that include
either the loss of E-cadherin or an increase in vimentin
expression, showed a significant increase of EMT following
cisplatin treatment in tumour tissues. The levels of E-Cadherin
were sustained the TZD/cisplatin treated group (TZD/CIS)
relative to the control group (ND/PBS) (Fig 1E). In parallel,
cisplatin-induced increases in vimentin levels were also
significantly reduced by combination with TZD (Fig 1F). These
observations prompted us to test whether endotrophin plays a
critical role in the cisplatin-driven increase of EMT, as
endotrophin plays a generalized role in EMT in tumour tissues
(Park & Scherer, 2012b). The question therefore is whether we
can connect the TZD-mediated decrease in COL6A3 levels
(Fig 1C) to the TZD-mediated enhanced cisplatin sensitivity
through suppression of the endotrophin-induced EMT.
Absence of COL6 sensitizes tumours to cisplatin treatment,
which is reversed by reconstitution with endotrophin
To assess the roles of COL6 in cisplatin resistance, we performed a
loss-of function study by utilizing the COL6/mice crossed with 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.PyMT mice (PyMT/COL6/). PyMT/COL6/ mice were
more sensitive to cisplatin treatment compared to PyMT mice
(Supporting Information Fig S2A). Notably, the tumour growth in
PyMT/COL6/ mice is delayed at the early onset of tumour
progression (Iyengar et al, 2005). To avoid the effects of COL6/
on tumour growth per se, we compared the chemo-sensitivitywith
size-adjusted tumours between PyMT/COL6/ and PyMT mice.
Even with size-adjusted tumours, cisplatin-induced tumour
regression was clearly enhanced in COL6/ mice as determined
by whole body imaging of tumour burden (Fig 2A). Tumour
burden in PyMT/COL6/mice was about twofold less than what
is seen in PyMT mice 3-weeks post-cisplatin treatment initiation
(Fig 2A), arguing that the absence of COL6 in tumour tissues
contributes to cisplatin sensitivity. Consistent with these
observations, we observed fourfold higher levels of apoptosis
in PyMT/COL6/ mice compared to PyMT mice (Supporting
Information Fig S2B), and cisplatin-induced MT levels were also
significantly decreased (Supporting Information Fig S2C).
To directly explore the effects of endotrophin in cisplatin
responsiveness, we utilized a gain-of function approach by
using transgenic mice overexpressing endotrophin, driven by a
MMTV-promoter. This limits endotrophin secretion to the local
tumour microenvironment (Park & Scherer, 2012b). MMTV-
endotrophin transgenic mice were reconstituted into PyMT/
COL6/ mice (i.e. PyMT/COL6//endotrophin mice). We
monitored this strain’s cisplatin sensitivity and compared it to
either PyMT or PyMT/COL6/ mice. The mRNA levels for
endotrophin in tumour tissues in PyMT/COL6//endotrophin
mice were about fivefold higher than those of endogenous levels
in PyMT mice, whereas no changes were seen at the level of
other COL6 chains (A1 and A2) or the remaining mature
portion of full-length COL6A3 chain (COL6A3-N) (Fig 2B).
Importantly, longitudinal measurements of whole body tumour
burden in PyMT mice showed that reconstitution of endotrophin
into PyMT/COL6/ mice conferred cisplatin resistance (Fig 2C).
Furthermore, the established reduced levels of pulmonary
metastasis in PyMT/COL6/ mice were also reversed by
endotrophin reconstitution (Fig 2D). This pinpoints the endo-
trophin cleavage fragment of COL6A3 as a necessary and
sufficient component of the full-length COL6A3 protein to induce
cisplatin resistance in otherwise COL6/ mice. In light of these
results, we started to focus our further analysis exclusively on
endotrophin, the fragment that we recently identified as a potent
tumour-promoting factor (Park & Scherer, 2012b).
Endotrophin, a cleavage product of COL6A3, confers cisplatin
resistance in tumour tissues
We have previously shown that MMTV-endotrophin mice
bred to the PyMT mice (PyMT/endotrophin) develop more
aggressive tumours compared to PyMT mice (Park & Scherer,
2012b). Here, we further examined these mice to see whether
endotrophin induces cisplatin resistance. PyMT/endotrophin
transgenic mice were treated with either PBS or cisplatin and
compared to PyMT control littermates. Primary tumour growth
of PyMT mice was effectively curbed with a high dosage of
cisplatin treatment (2.5mg/kg, ip. twice a week), whereas
PyMT/endotrophin mice were resistant to the effects of cisplatinEMBO Mol Med (2013) 5, 935–948
www.embomolmed.org Research Article
Jiyoung Park et al.
Figure 2. The absence of COL6 in PyMT mice sensitizes tumours to cisplatin treatment.
A. Eleven week old FP635/PyMT and FP635/PyMT/COL6/ mice were given cisplatin (1 mg/kg, ip., 2 times/week) or PBS over the course of tumour progression.
Tumour burden at a whole body level was monitored with a fluorescence scanner (IVIS) once a week. Representative images and quantification showing
increased cisplatin sensitivity in PyMT/COL6/ mice. Tumour burden at the end point was determined and represented as mean SD (n¼5/group).
p¼ 0.0294 versus FP635/PyMT/CIS by Mann–Whitney t-test.
B. Total RNA was prepared from the tumour tissues from PyMT, PyMT/COL6/ and PyMT/COL6//ETP mice. mRNA levels for the COL1A1, COL6A1, -A2, -A3-N
(amino-terminus of COL6A3) and ETP were determined by qRT-PCR. Values were normalized with 36B4 and represented as mean SD (n¼ 4/group). Relative
values of each gene are represented as fold increase over PyMT. p< 0.001 versus PyMT by two-way ANOVA.
C,D. Eleven week old FP635/PyMT/COL6/ (COL6/) and FP635/PyMT/COL6//Endotrophin (COL6//ETP) mice were given cisplatin for 6-weeks compared
to PyMT control littermates (Ctrl). Tumour burden was determined by fluorescence signal intensity during the cisplatin treatment (C). Fold increase
over PyMT in pretreatment represents mean SD (n¼5–6/group). p<0.01 PyMT (CIS) versus PyMT/COL6/ (CIS); ##p< 0.01, PyMT/COL6/ (CIS)
versus PyMT/COL6//ETP (CIS) by two-way ANOVA. Metastatic burden at the end point was determined with lung tissues and represented as
mean SD (n¼5–6/group) (D). p¼ 0.0047 COL6/ versus COL6//ETP by Mann–Whitney t-test.treatment (Fig 3A). Similarly, allografts of tumour pieces taken
from PyMT and PyMT/endotrophin mice transplanted into
isogenic wild-type mice showed that endotrophinþ-tumours
were more resistant to a lower dosage of cisplatin treatment
(1mg/kg, ip. twice a week) compared to control (Ctrl)-tumours
(Fig 3B and C). These results further corroborate a direct
connection of cisplatin-induced high levels of endotrophin
expression and chemo-resistance.
Association of endotrophin with epithelial–mesenchymal
transition and chemo-sensitivity
Endotrophin has multiple effects on tumour progression
through TGF-b-dependent EMT and fibrosis, as well as TGF-EMBO Mol Med (2013) 5, 935–948 b-independent chemokine activities that trigger the recruitment
of endothelial cells and macrophages, resulting in enhanced
angiogenesis and inflammation (Park & Scherer, 2012b). Having
implicated endotrophin as a critical mediator of cisplatin
resistance, we wanted to further substantiate the endotro-
phin-induced EMT as a downstream readout for cisplatin
resistance acquisition by utilizing a histological approach.
Endotrophin levels in PyMT mice were modulated genetically
with MMTV-endotrophin transgenic mice for overexpression
and with COL6/ mice to reduce the levels. Alternatively,
endotrophin levels were reduced pharmacologically with TZD
treatment. Consistent with themRNA levels of endotrophin seen
in Fig 1C, cisplatin significantly increased the endotrophin2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 939
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Figure 3. Endotrophin overexpression confers cisplatin resistance in PyMT mice.
A. Ten week old PyMT and PyMT/endotrophin (PyMT/ETP) mice were given high dosage of cisplatin (2.5 mg/kg, ip., 2 times/week). Tumour growth was
determined by caliper measurements. Data represent mean SD (n¼7–10/group). p<0.001, PyMT/CIS versus PyMT/ETP/CIS by two-way ANOVA.
B,C. A piece of tumours taken from PyMT (Ctrl-tumour) and PyMT/endotrophin (ETPþ-tumour) mice were implanted into isogenic wild-type hosts. Cisplatin
(1 mg/kg, ip., 2 times/week) were injected at 3-weeks post-implantation for tumour progression. Tumour volume was determined by caliper measurement.
Quantification (B) and representative images (C) showing increased cisplatin resistance in ETPþ-tumours. Data represent mean SD (n¼7–8/group).
p< 0.05 versus Ctrl-tumours by two-way ANOVA. Representative images were taken at 70-days post-implantation. Scale: 10 mm.
940protein levels in tumour tissues (Fig 4A). In contrast,
endotrophin protein levels were dramatically reduced in tumour
tissues of both COL6/ and TZD treatment groups compared to
controls (Fig 4A). Histologically, we observed that necrotic
lesion areas were increased by cisplatin treatment in all groups
(Fig 4B) regardless of the levels of endotrophin in the PyMT
setting. Immunostaining for the loss of E-cadherin showed a
significant increase of EMT following cisplatin treatment in
all groups except for the group with the combination therapy
with TZD (Fig 4C). This suggests that the cisplatin-induced EMT
is curbed by TZD treatment. Consistent with this observation,
immunostaining for vimentin (a mesenchymal cell marker),
reveals significantly increases in response to cisplatin. This
increase in vimentin was further augmented by endotrophin,
whereas both COL6/ and TZD groups displayed decreased
vimentin levels (Fig 4D). This suggests that the cisplatin-
mediated acquisition of mesenchymal cell-like traits during
the EMT process is linked to endotrophin levels. This also
indicates that the modulation of endotrophin levels by either
genetic or pharmacological means is tightly associated with
EMT levels in tumour tissues, and this correlative decrease
of endotrophin and EMT at least partly accounts for the
increased cisplatin sensitivity observed in the COL6/ or TZDs
combination groups (Fig 4E).
Acquisition of the beneficial effects of TZDs to cisplatin
critically depends on the endotrophin levels
We have shown that the beneficial effects of TZDs on the
cisplatin therapeutic efficiency are linked to endotrophin down-
regulation. Do the TZD effects converge on to the endotrophin-
mediated signaling pathways? BothmRNA and protein levels for
endotrophin were dramatically reduced with the TZD and 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.cisplatin combination treatment (Figs 1C and 4A, respec-
tively). Therefore, we assessed whether endotrophin over-
expression could abolish the beneficial effects of TZD on
cisplatin efficacy. Endotrophinþ-cancer cells originating from
PyMT/endotrophin mice were compared to Ctrl-cancer cells
from PyMT mice, and were implanted into wild-type mice.
TZDwas given to wild-type hosts 10 days prior to implantation
and cisplatin was injected intraperitoneally every 5 days,
starting 3-weeks post-implantation when the tumour volume
reached 100mm3 (Fig 5A). Endotrophinþ-tumours were
more resistant to cisplatin treatment compared to Ctrl-
tumours (Fig 5B, Ctrl/ND vs. ETP/ND), and this increase
was markedly attenuated by the combination with TZD
(Fig 5B, ETP/ND vs. ETP/TZD). This suggests that TZD
influences not only the endotrophin expression per se, but it
may also impact the downstream pathways of endotrophin.
However, we cannot rule out that endotrophin-independent
pathways are also contributing, or that TZD acts on host
endotrophin levels in this transplantation paradigm. Defined
necrotic lesion areas, as assessed by H&E stains, were
significantly decreased in endotrophinþ-tumours. This phe-
nomenon was however reversed by combined treatment of
cisplatin with TZD (Fig 5C). This suggests that a combination
of TZD with cisplatin confers sensitivity to endotrophinþ-
tumours. Accordingly, the significant endotrophin-mediated
increase on EMT, angiogenesis and fibrosis seen in
endotrophinþ-tumours was suppressed by the combination
of cisplatin with TZD, as judged by immunostaining for
vimentin (EMT), lectin perfusion (angiogenesis) andMasson’s
trichrome C stain (fibrosis), respectively (Fig 5D–F). This
suggests that TZD attenuates the downstream signaling path-
ways induced by endotrophin.EMBO Mol Med (2013) 5, 935–948
www.embomolmed.org Research Article
Jiyoung Park et al.
Figure 4. Histological analysis of tumours in PyMT mice with different levels of endotrophin after chemotherapy.
A. Endotrophin staining and quantification, showing increased endotrophin levels upon cisplatin treatment which was further augmented in PyMT/endotrophin
mice, whereas it was barely detectable in PyMT/TZD and PyMT/COL6/ mice. p¼0.0174, ##p¼ 0.009, #p¼ 0.024 and ###p¼ 0.0004.
B. H&E staining and necrotic lesion area quantification on tumours, showing increased cell death after cisplatin treatment in all groups, and further augmented
sensitivity in PyMT/TZD. p¼ 0.0463.
C. E-cadherin staining and quantification, showing decreased membrane integrity of epithelial cancer cells after cisplatin treatment in PyMT mice. TZD reverses
cisplatin-induced loss of E-cadherin levels. p¼0.0045 and #p¼0.0285.
D. Vimentin staining and quantification, showing increased EMT in PyMT/endotrophin mice, whereas it was decreased in PyMT/TZD and PyMT/COL6/ mice.
p¼0.0085 and #p¼ 0.0111. Quantified results represent mean SD (multiple images from n¼ 5–6/group). Statistics (PBS vs. CIS; #CIS vs. ETP/CIS, TZD/CIS,
or COL6//CIS) were analysed by unpaired Student’s t-test. Scales: 50mm (A), 200mm (B) and 100mm (C–D).
E. Hypothetical modeling of cisplatin responsiveness in PyMT mice relying on the endotrophin levels and EMT status. Arrow indicates TZD augments chemo-
sensitivity through suppression of endotrophin levels and EMT.
EMBO Mol Med (2013) 5, 935–948  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 941
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Figure 5. TZD enhances cisplatin sensitivity through suppression of endotrophin-mediated EMT, fibrosis and angiogenesis.
A,B. Schematic diagram for allografts (A), indicating cancer cells were isolated from tumours in PyMT (Ctrl) and PyMT/endotrophin (ETP) mice and implanted into
wild-type hosts (0.5 106 cells/mouse). Host mice were given TZD (20 mg/kg) or ND diet at 10 days before implantation for tumour progression. Cisplatin
(1 mg/kg, ip., every 5 days) was administered at 3-weeks post-implantation. Quantification of tumour volume (B), showing TZD suppressed tumour growth in
endotrophinþ-tumours. Data represent mean SD (n¼8–9/group). p¼ 0.05, p¼0.01 and p¼ 0.001 Ctrl/ND versus ETP/ND; ##p¼0.01 and
###p¼ 0.001 ETP/ND versus ETP/TZD by unpaired Student’s t-test.
C–F. Histological analysis of tumours in allografts after cisplatin treatment. H&E staining and necrotic area quantification (C), showing significantly increased
chemo-sensitivity in endotrophinþ tumours upon combination of TZD with cisplatin. Necrotic area (). p<0.0001 and ##p¼ 0.0018. Vimentin staining
quantification (D), showing decreased EMT in both Ctrl- and endotrophinþ-tumours by TZD. p< 0.0001 and ###p<0.0001. Quantification of perfused
lectin staining (E), showing the increased functional blood vessels in endotrophinþ-tumours was decreased by TZD. p¼ 0.015, p¼0.001 and ##p¼0.0088.
Masson’s Trichrome C staining quantification (F), showing increased fibrosis in endotrophinþ-tumours was decreased by TZD. p<0.0001 and
##p¼ 0.0013. Scales: 200mm (A), 100mm (D–E) and 50mm (F). Statistics (Ctrl/ND/CIS vs. Ctrl/TZD/CIS or ETP/ND/CIS; #ETP/ND/CIS vs. ETP/TZD/CIS) were
analysed by unpaired Student’s t-test.
942  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 935–948
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suppressed by TZDs, we predicted that COL6/micewould have
a remaining, though reduced benefit from a TZD combination
with cisplatin. To address this point, we assessed the TZD impact
on cisplatin treatment in PyMT/COL6/ mice and compared
them to PyMT mice. Indeed, the beneficial effects of TZD on
cisplatin sensitivity were not seen in PyMT/COL6/ mice, i.e.
tumour regression was unaffected by TZD combined with
cisplatin treatment in PyMT/COL6/ (Fig 6A). Necrotic lesions
were barely detectable in the PyMT/COL6//TZD/CIS group
relative to PyMT/COL6/ or PyMT/COL6//TZD groups
(Fig 6B). As expected, the TZD effects on EMT suppression were
not observed in PyMT/COL6/ mice (Fig 6C–D). These results
lend further support to the notion that the beneficial effects of
TZDs are critically dependent on the suppression of endotrophin
activity. In other words, the endotrophin levels in association
with progression towards EMT are critical determinants of the
beneficial effects of TZDs on cisplatin treatment.
The suppression of endotrophin activity can be achieved by
either using TZD or anti-endotrophin monoclonal antibodies,
both of which sensitize tumours to cisplatin therapeutics
As a last step, we determined therapeutic potential of a
previously described endotrophin-neutralizing antibody (clone
10B6) on cisplatin sensitivity. Tumour pieces taken from PyMT
mice were implanted into wild-type mice and treated with
cisplatin alone or in combination with either TZD or 10B6 once
the tumour volume reached 100mm3. Tumour regression was
monitored for 2-months post-implantation. We see that both
TZD and 10B6 treatment efficiently sensitized the tumours
to cisplatin treatment (Fig 7A). We also utilized xenograft
models with the mammary carcinoma cell line 4T1, which is
highly invasive and rapidly metastasizes throughout the body,
resembling human stage IV breast cancer (Pulaski & Ostrand-
Rosenberg, 1998). Nude mice were injected with 4T1 cells
in mammary adipose tissues. Treatment with cisplatin was
initiated when the tumour volume reached at 100mm3, which
was combined with either control IgGs or 10B6. Treatment of
either 10B6 or cisplatin alone for 28-days barely inhibited
primary tumour growth of 4T1, while treatment with cisplatin
combined with 10B6 induced a moderate, but significant
inhibition in comparison to cisplatin or 10B6 alone (Fig 7B).
However, most prominent effects of combination treatment
(cisplatin and 10B6) were observed on metastatic growth. The
metastatic burden on the lung, as determined by assessing
the metastatic lesion areas, was significantly attenuated
by combination treatment relative to individual treatments
(Fig 7C). Notably, the combination of cisplatin and endotrophin
neutralization showed a particularly higher efficacy on meta-
static growth than either treatment alone for late stages of
4T1 carcinomas. Furthermore, a subset of genes related to EMT
that includes Vimentin, Twist1 and S100A4 levels were also
significantly decreased by the combination treatment (Fig 7D).
This indicates that inhibitory effects of combination treatment of
cisplatin with endotrophin neutralization mediate a suppression
of EMT, lack of which results in loss of crucial traits for
metastatic growth.EMBO Mol Med (2013) 5, 935–948 DISCUSSION
Building on our previous studies, we tested the cellular
responses to endotrophin on chemo-responsiveness in mam-
mary tumours treated with cisplatin. We demonstrate that a
robust response of cancer cells to cisplatin is highly dependent
on the presence of the endotrophin-driven EMT process.
Endotrophin overexpression, leading to enhanced EMT, causes
cisplatin resistance. In contrast, the suppression of endotrophin
levels by either using a COL6/ mouse model or a TZD
combination sensitizes cancer cells to cisplatin treatment. Our
data presented here suggests that determining endotrophin
levels in association with the EMT status is critical for predicting
cisplatin response. Higher levels of endotrophin occur in
advanced metastatic breast cancers (Iyengar et al, 2005) and
contribute to the poor chemo-response. It also suggests that this
subset of tumours is likely to undergo EMT, which plays a major
role in tumour progression, metastasis and multi-drug resis-
tance in various epithelial cancer cells (Haslehurst et al, 2012;
Latifi et al, 2011; Rosano et al, 2011). Furthermore, we propose
that obesity is one of the major risk factors to provide an
endotrophin-enriched tumour microenvironment, because it is
mainly secreted from adipose tissue and elevated in dysfunc-
tional adipose tissue. Therefore, it will be interesting to see if the
endotrophin-mediated EMT we described here is also predictive
of a poor chemotherapeutic response in other types of cancers.
Our results are consistent with clinical studies showing that
cancer cells with high levels of COL6A3 show a reduced
response to platinum-based chemotherapy than tumours with
low levels of COL6A3 (Bonaldo et al, 1998; Iyengar et al, 2005;
Sherman-Baust et al, 2003; Varma et al, 2005). However,
evidence for a direct connection between these two phenomena
was lacking. It has been appreciated that there is an enormous
degree of ECM remodeling going on in response to chemother-
apy, and this in turn has an impact on drug penetration, which
critically affects chemo-sensitivity. In addition, increased tissue
stiffness seems to confer survival signals to cancer cells through
enhanced anchoring of cancers to ECMs. Beyond these purely
mechanical roles of ECM remodeling, we found here that
endotrophin acts as a signaling molecule leading to an enhanced
EMT process, resulting in cisplatin resistance.
The beneficial effects of the combination of TZDs with
platinum-based chemotherapy are appreciated. Based on our
data, TZD monotherapy fails to have an impact on tumour
progression in PyMT mice, and in fact further enhances growth.
This is consistent with clinical reports that failed to see an impact
on the malignancies of epithelial cancer cells (Burstein et al,
2003; Kulke et al, 2002; Smith et al, 2004). However, TZDs in
combination with cisplatin are highly beneficial. How do TZDs
enhance cisplatin effectiveness? Here, we show that the beneficial
effects of TZDs on cisplatin therapies are due to marked reduction
of the endotrophin levels. This attenuates the downstream
consequences of endotrophin signaling, including a suppression
of EMT, fibrosis and angiogenesis, thereby leading to an increase
of chemo-sensitivity (Fig 7E). Therefore, a treatment criterion for
a TZD/cisplatin combination therapy would be high levels of
endotrophin in association with EMT, due to the fact that the2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 943
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Figure 6. Bypassing endotrophin-downstream pathways with COL6/ mice abolishes beneficial effects of TZD on cisplatin sensitivity.
A. PyMT/COL6/ mice were given TZD (20 mg/kg) or ND at 8 weeks of age. Cisplatin (1 mg/kg, ip., 2 times/week) or PBS treatment was initiated in 10 week old
mice. Tumour growth was determined by caliper measurements, and PyMT littermates given TZD were represented as a control. Data represent mean SD
(n¼ 6–8/group).
B–D. Histological analysis. H&E staining and necrotic area quantification (B), showing no necrotic area in PyMT/COL6/ mice following TZD combination with
cisplatin treatment. EMT was determined by immunostaining for E-Cadherin (C) and Vimentin (D), showing no significant effects in TZD/CIS groups
comparable to non-treated groups (PBS). Data represent mean SD (multiple images from n¼5–6/group). p¼n.s (no significant) versus PyMT/COL6//TZD
by unpaired Student’s t-test. Scales: 200mm.
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Figure 7. Neutralizing endotrophin activity with monoclonal antibodies sensitizes tumours to cisplatin treatment.
A. Pieces of tumours from PyMT mice were implanted into wild-type hosts. Tumour-bearing mice were given cisplatin (1 mg/kg, ip., every 5 days) or PBS,
combined with either TZD (20 mg/kg) or anti-endotrophin monoclonal antibodies (100mg/mouse, once a week) for tumour progression. Tumour volumes
were determined by caliper measurements. Data represent mean SD (n¼5/group). p<0.05, p<0.01, p< 0.001 versus Cisplatin by two-way ANOVA.
B–D. 4T1 (0.5 106 cells/mouse) cells were xenografted in nude mice and monitored tumour growth (B) and metastasis (C). Cisplatin (1 mg/kg, every 5 days, i.p)
with either 10B6 or IgG control (100mg/mouse, once a week, i.p) was given to tumour-bearing mice from 12-days after implantation. Tumour volumes were
determined by caliper measurements. Data represent mean SD (n¼5/group). p<0.05, p< 0.001 versus Cisplatinþ IgG by two-way ANOVA. Metastatic
burden was determined by measuring metastatic lesion area in lung tissues with H&E stains. Quantified data represent mean SD (n¼5/group).
p¼ 0.0007 and p¼ 0.0209 versus CIS/10B6 by unpaired Student’s t-test. mRNA levels for EMT markers such as vimentin, snail, slug, twist1, twist2 and
S100S4 were determined by RT-qPCR (D). Values are normalized with 36B4 and represented as mean SD (n¼5/group). p¼0.0070, p¼0.0045,
p¼ 0.0022 for vimentin, twist1 and S100A4, respectively by unpaired Student’s t-test.
E. Summary of the study. Increased endotrophin following cisplatin treatment confers cisplatin resistance, and beneficial effects of TZDs on cisplatin
sensitivity are mediated through both a suppression of endotrophin levels and its downstream pathways, including EMT, fibrosis and angiogenesis.
EMBO Mol Med (2013) 5, 935–948  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 945
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The paper explained
PROBLEM:
The therapeutic benefit of cisplatin in human cancer treatments
is often limited due to resistance. TZDs (peroxisome proliferator
activated receptor g agonists) show beneficial effects in the
context of cisplatin-based chemotherapy. Our previous work
indicates that collagenVIa3 (COL6A3) plays an important role in
cisplatin resistance. However, the detailed molecular mechan-
isms underlying the correlations between COL6A3 and cisplatin
resistance remained elusive. The goal of this study was to
elucidate the roles of endotrophin, a cleavage product of COL6A3,
in cisplatin resistance and elaborate further to see if endotrophin
modulates the beneficial effects of TZDs in cisplatin therapeutics
in breast cancer.
RESULTS:
Gain- and loss-of function studies were conducted with MMTV-
endotrophin transgenic and COL6 null animals (COL6/) in
the background of MMTV-PyMT mice, respectively. We
demonstrate that endotrophin, which is mainly secreted from
stromal adipocytes in the tumour microenvironment, confers
a high degree of cisplatin resistance by enhancing epithelial–
mesenchymal transition, fibrosis and angiogenesis. Furthermore,
the powerful beneficial effects of TZDs on cisplatin sensitivity
are mainly due to a marked inhibition of endotrophin-
mediated activities. This suggests that TZDs directly mediate
enhanced cisplatin chemosensitivity through a downregulation
of endotrophin. Treatment with an endotrophin neutralizing
monoclonal antibody in combination with cisplatin very
effectively inhibits tumour growth of allografts of MMTV-PyMT
tumours.
IMPACT:
It is well appreciated that chemo-responsiveness is changed over
the course of tumour progression, and it varies greatly between
different tumour types; identifying the critical players mediating
this chemo-resistance is important to devise better therapeutic
strategies. Our results have clinical implications, as endotrophin
is increased in tumours upon chemotherapy, and the associated
EMT is a predictor of chemo-resistance. Therefore, endotrophin
levels can be a strong prognostic marker with respect to the
tumour response to combination therapy of TZDs with cisplatin,
and the neutralization of endotrophin further improves the
therapeutic response to combination therapy.
946beneficial effects of TZDs are acquired through a direct
suppression of endotrophin-induced EMT (Fig 4E). Along those
lines, we show that neutralizing endotrophin activity through
the use of neutralizing monoclonal antibodies during cisplatin
treatment effectively inhibits the tumour growth and metastasis.
In summary, we have employed a rodent model for a
chemotherapeutic tumour response, and demonstrated that the
endotrophin-mediated induction of the EMT results in chemo-
resistance. Furthermore, we highlighted that the beneficial
effects of TZDs on cisplatin-based therapies are mediated
through the suppression of this pathway. Bypassing the
endotrophin-induced EMT in the context of COL6/ mice
diminished the TZDs-mediated beneficial effects on cisplatin
therapeutics and resulted in a poor response. These results
provide a direct explanation for previous correlations reported
in the context of poor responses to platinum-based chemother-
apy in tumours expressing high levels of COL6. This also
suggests that endotrophin levels as a promising predictive
marker to decide if a TZD combination should be initiated along
with a platinum-based therapeutic approach.MATERIALS AND METHODS
Animal experiments
All animal experiments were approved by the Institutional Animal
Care and Research Advisory Committee at the University of Texas
Southwestern Medical Center. MMTV-PyMT mice (Guy et al, 1992) 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.were used as a mouse mammary tumour model. COL6 knockout
(COL6/) mice were generated as previously described by Bonaldo
et al (1998). MMTV-endotrophin transgenic mice and MMTV-FP635
(Infrared fluorescent protein FP635) transgenic mice were generated
as previously described in our study (Park & Scherer, 2012a). All
experiments were conducted using littermate-controlled female mice.
All animals used in this study are in a pure FVB background.
Reagents
Cisplatin (Sigma, 479306) was diluted to 1mg/ml in PBS and was
sonicated briefly before injection. The PPARg agonist rosiglitazone
(Avandia, GlaxoSmithKline) was given by diet inclusion at a dose of
20mg/kg/day BW. Anti-mouse endotrophin monoclonal antibodies
(10B6, 100mg/mouse) were administered by intraperitoneal injection.
Histological analysis
Formalin-fixed paraffin-embedded tissue sections were used for
immunostaining. Deparaffinized tissue slides were stained with rabbit
anti-mouse endotrophin, MT (Abcam, Ab12228), E-cadherin (Cell
signaling, 24E10), Vimentin (Cell signaling, D21H3) and cytokeratin
(Cell Signaling, #4545). For immunofluorescence, fluorescence labeled
secondary antibodies were used and counterstained with DAPI. Images
were acquired using the Leica confocal microscope and analysed with
ImageJ software. For immunohistochemistry, the reaction was
visualized by the DAB Chromogen-A system (Dako Cytomation) and
counterstained with haematoxylin. Images were acquired using the
Nikon Cool Scope. TUNEL assay was according to the manufacturer’s
protocol (Trevigen, Inc). To assess functional blood vessels formation inEMBO Mol Med (2013) 5, 935–948
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(100mg, i.v) (Vector laboratories, CA) and perfused lectin was
visualized by a Cy3-labeled streptoavidin. H&E staining and Masson’s
Trichrome C staining were performed by Dr. John Shelton at the
University of Texas Southwestern Medical Center. Histological analysis
was performed with pathologists in the UTSW pathology core facility.
Quantitative RT-PCR
Total RNA was isolated following tissue homogenization in Trizol
(Invitrogen, Carlsbad, CA) using a TissueLyser (Qiagen, Valencia, CA) and
isolated using the RNeasy kit (Qiagen). Total RNA (1mg) was reverse
transcribed with SuperScript III reverse transcriptase (Invitrogen). Quanti-
tative real-time PCR (qRT-PCR) was performed in the Roche Lightcycler
480. For all qRT-PCR experiments, the results were calculated using the
DDCt method using 36B4 to normalize. Primers for COL1A1, COL6A1,
COL6A2 and COL6A3 were followed in previous report (Khan et al, 2009).
Other primer sequences used in this study are listed in Supporting
Information Table S1.
Primary culture of mammary cancer cells and implantation
Mammary epithelial cancer cells were isolated as described in
previous report (Park et al, 2010). One day after cell culture, same
amount of cancer cells were counted and implanted into inguinal fat-
pad of 8-to 10-week-old indicated recipient mice by intraductal
injection. Tumour growth was determined from 10 days after
implantation and twice a week over the course of tumour progression.
Analysis of tumour progression
Tumour onset was monitored twice weekly by palpation. Tumour
sizes were measured with a digital caliper twice weekly and the
volumes were calculated as (lengthwidth2)/2. Inguinal tumours was
weighted to determine tumour burden. Animals were sacrificed when
the tumour burden visibly affected the host or when the tumours
reached the IACUC predetermined limit of 20mm along one axis.
Tumour imaging
Infrared fluorescence expressing MMTV-PyMT mice (FP635/PyMT)
were imaged by IVIS scanner (Caliper lifesciences) and signal intensity
was analysed with Living image v.3.2 (Caliper lifesciences).
Statistical analyses
All data represent mean SD. Data were analysed by two-way ANOVA
followed by Newman–Keuls multiple comparison test or by Student’s
t-test and Mann–Whitney t-test, as appropriate with GraphPad Prism
v.5 software. p-value <0.05 was considered as statistical significance.Author contributions
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